Pieter H. Reitsma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pieter H. Reitsma has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Mettine H. A. Bos
Department of Internal medicine, division of Thrombosis and Hemostasis, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands
2 shared publications B. A. Hutten
Department of Clinical Epidemiology & Biostatistics, Academic Medical Center, Amsterdam, The Netherlands
1 shared publicationB. Rekké
Laboratory for Experimental Internal Medicine
1 shared publicationB. S. Dragt
Department of Plasma Proteins, Sanquin-AMC Landsteiner Laboratory, Amsterdam, The Netherlands
1 shared publication- Begüm Kocatürk
Hacettepe University, Ankara, Türkiye, Turkey (Türkiye)
1 shared publication - Betül Ünlü
Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (11) , 3895-3907
Pseudonaja textilis venom factor Va circumvents natural regulatory mechanisms via a unique A2 domain region
- 31 August 2026
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 24 (11) , 3895-3907
Open AccessPseudonaja textilis venom factor Va circumvents natural regulatory mechanisms via a unique A2 domain region
- Open Access
- 30 April 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (6) , 416-424
Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort
Background: Major bleeding occurs annually in 1%–3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk.Aim: To determine the association of genetic variants (cytochrome P450 enzymes 2C9 [CYP2C9] and 4F2 [CYP4F2], gamma‐glutamyl carboxylase [GGCX]) with major bleeding in VKA users, separately and combined, including vitamin K epoxide reductase complex subunit‐1 (VKORC1).Methods: A case‐cohort study was established within the BLEEDS cohort, which includes 16,570 patients who initiated VKAs between 2012 and 2014. We selected all 326 major bleeding cases that occurred during 17,613 years of follow‐up and a random subcohort of 978 patients. We determined variants in CYP2C9, CYP4F2, GGCX, VKORC1 and evaluated the interaction between variant genotypes. Hazard ratios for major bleeding with 95% confidence intervals (95% CI) were estimated by weighted Cox regression.Results: Genotype was determined in 256 cases and 783 subcohort members. Phenprocoumon was the most prescribed VKA for both cases and the subcohort (78% and 75%, respectively). Patients with major bleeding were slightly older than subcohort patients. CYP4F2‐TT carriership was associated with a 1.6‐fold (95% CI 0.9–2.8) increased risk of major bleeding compared with CC‐alleles, albeit not statistically significant. For the CYP2C9 and GGCX variants instead, the major bleeding risk was around unity. Carrying at least two variant genotypes in CYP2C9 (poor metabolizer), CYP4F2‐TT, and VKORC1‐AA was associated with a 4.0‐fold (95%CI 1.4–11.4) increased risk, while carriers of both CYP4F2‐TT and VKORC1‐AA had a particularly increased major bleeding risk (hazard ratio 6.7, 95% CI 1.5–29.8) compared with carriers of CC alleles in CYP4F2 and GG in VKORC1. However, the number of major bleeding cases in carriers of multiple variants was few (8 and 5 patients, respectively).Conclusions: CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.
- 30 April 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (6) , 416-424
Open AccessGenetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort
Background: Major bleeding occurs annually in 1%–3% of patients on vitamin K antagonists (VKAs), despite close monitoring. Genetic variants in proteins involved in VKA response may affect this risk.Aim: To determine the association of genetic variants (cytochrome P450 enzymes 2C9 [CYP2C9] and 4F2 [CYP4F2], gamma‐glutamyl carboxylase [GGCX]) with major bleeding in VKA users, separately and combined, including vitamin K epoxide reductase complex subunit‐1 (VKORC1).Methods: A case‐cohort study was established within the BLEEDS cohort, which includes 16,570 patients who initiated VKAs between 2012 and 2014. We selected all 326 major bleeding cases that occurred during 17,613 years of follow‐up and a random subcohort of 978 patients. We determined variants in CYP2C9, CYP4F2, GGCX, VKORC1 and evaluated the interaction between variant genotypes. Hazard ratios for major bleeding with 95% confidence intervals (95% CI) were estimated by weighted Cox regression.Results: Genotype was determined in 256 cases and 783 subcohort members. Phenprocoumon was the most prescribed VKA for both cases and the subcohort (78% and 75%, respectively). Patients with major bleeding were slightly older than subcohort patients. CYP4F2‐TT carriership was associated with a 1.6‐fold (95% CI 0.9–2.8) increased risk of major bleeding compared with CC‐alleles, albeit not statistically significant. For the CYP2C9 and GGCX variants instead, the major bleeding risk was around unity. Carrying at least two variant genotypes in CYP2C9 (poor metabolizer), CYP4F2‐TT, and VKORC1‐AA was associated with a 4.0‐fold (95%CI 1.4–11.4) increased risk, while carriers of both CYP4F2‐TT and VKORC1‐AA had a particularly increased major bleeding risk (hazard ratio 6.7, 95% CI 1.5–29.8) compared with carriers of CC alleles in CYP4F2 and GG in VKORC1. However, the number of major bleeding cases in carriers of multiple variants was few (8 and 5 patients, respectively).Conclusions: CYP4F2 polymorphism was associated with major bleeding, especially in combination with VKORC1 genetic variants. These variants could be considered to further personalize anticoagulant treatment.
- Open Access
- 14 July 2015
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 13 (9) , 1683-1693
Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression
- 14 July 2015
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 13 (9) , 1683-1693
Open AccessAlternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression
- 20 August 2012
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 10 (10) , 2168-2178
Formation of platelet‐binding von Willebrand factor strings on non‐endothelial cells
- 20 August 2012
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 10 (10) , 2168-2178
Formation of platelet‐binding von Willebrand factor strings on non‐endothelial cells
- 23 June 2004
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (7) , 1104-1109
Non‐fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX
- 23 June 2004
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 2 (7) , 1104-1109
Non‐fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX